Learn how you can stall the development of full-blown Multiple Myeloma with evidence-based nutritional and supplementation therapies.
Click the orange button to the right to learn more.
MGUS diabetes metformin may be a three magic words for people diagnosed with monoclonal gammopathy of undetermined significance (MGUS is a form of pre-myeloma) as well as diabetes.
However, I believe it is important to understand the risks and benefits of any and all therapies- conventional or non. I mean, even drinking too much water too fast can cause serious health problems.
Metformin is a commonly prescribed medication for managing type 2 diabetes. It works by decreasing the amount of sugar produced by the liver and increasing the sensitivity of muscle cells to insulin. In recent years, there has been growing interest in using metformin for various purposes beyond diabetes treatment, such as anti-aging, weight loss, and potential cancer prevention.
Here are some potential risks and benefits associated with supplementing with metformin:
I guess I’m writing this blog post for diabetics who have been diagnosed with pre-myeloma in particular because a chemotherapy called dexamethasone is prescribed throughout the journey of the average myeloma patient. And dexamethasone is a glucosteroid that caused a person’s blood sugar to spike.
Myeloma is a challenge for the diabetic patient.
Have you been diagnosed with MGUS? Are you diabetic or pre-diabetic? Let me know- David.PeopleBeatingCancer@gmail.com.
“Multiple myeloma (MM) arises from asymptomatic precursor states, monoclonal gammopathy of undetermined significance (MGUS) or smoldering multiple myeloma (SMM) [1,2]… Although the survival of MM has improved dramatically due to several major therapeutic advances in recent years, MM remains incurable and is associated with significant morbidity .
Metformin is a widely used drug for diabetes that has been shown to reduce the risk of developing multiple solid cancers among diabetics …
In conclusion, we have shown that anti-diabetic medications may have a protective effect on the development of MM in diabetic patients with MGUS. These results add to previous data by Chang et al and other studies showing a protective effect of metformin on the development of cancer . Preclinical studies have also shown anti-myeloma effects of metformin [16,17]. Future studies should address the effect of tight glycemic control, in addition to other metformin-specific mechanisms, on MGUS progression to MM in diabetic patients. MM will be an increasing burden on our population due to aging and increasing rates of obesity. Therefore, exploring opportunities to prevent the development of MM is critical…”
The findings “corroborate the largely consistent evidence from other observational studies showing an association between metformin use and lower dementia incidence [and] may have important implications for clinical treatment of adults with diabetes,” the authors write.